Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2013

View Archived Issues

Elimination of leukemia stem cells observed for PF-04449913

Novel oncolytic agents with epigenetic targets described

Shire updates accomplishments of fourth quarter 2012

Small molecules targeting RNA improve experimental myotonic dystrophy type 1

Trial of temsirolimus in prostate cancer stopped prematurely

Boehringer Ingelheim divulges new LTA-4 hydrolase inhibitors

Georgia State University patents novel cyanine dyes for cancer

Abbott Laboratories prepares new protein kinase inhibitors

German group discloses novel TRPV1 ligands

Researchers at Allergan disclose novel alpha2-adrenoceptor agonists

CS-6 shows activity against ovarian cancer stem cells

PIQUR Therapeutics secures funding to develop innovative anticancer therapies

Roche and Chiasma enter into a collaboration agreement for Octreolin

FDA grants orphan drug status to SOV's testosterone undecanoate

Idursulfase beta gains orphan drug status in U.S.

FDA grants orphan drug status to diabetes vaccine candidate

Regeneron and Bayer initiate new phase III aflibercept study

FDA accepts lixisenatide NDA for review

Theracrine synthesizes new fascin inhibitors for cancer

Vorsetuzumab mafodotin shows promising activity in patients with CD70-positive RCC

Edison reports initiation of phase II study of EPI-743

New androgen receptor agonists divulged by Novartis

Novel inhibitors of tankyrase synthesized at Novartis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...